衣达拉奉联合氯吡格雷治疗急性脑梗死患者的疗效及对NIHSS评分的影响

目的观察依达拉奉联合氯吡格雷治疗急性脑梗塞患者的疗效及对NIHSS评分的影响。方法所有病例均来自于我院2010年3月～2011年3月收治的64例急性脑梗死患者，根据治疗方法不同分为治疗组（依达拉奉联合氯吡格雷治疗）和对照组（依达拉奉治疗）各32例，比较两组治疗14d后的疗效及治疗前、治疗7d后、治疗14d后两组的NIHSS评分变化情况。结果治疗组与对照组治疗14d后的有效率为93．8％和75．0％，差异显著（P〈0．05）。治疗7d后，两组NIHSS评分均较治疗前明显降低，且治疗组较对照组降低更显著（P〈0．05）；治疗14d后，两组NIHSS评分较治疗前及治疗后7d明显降低，且治疗组较对照组降低更显著（P〈0．05）。结论依达拉奉、氯吡格雷联合治疗急性脑梗死具有协同作用，能有效改善神经功能缺损．提高临床疗效．值得推广和应用。

The treatment efficacy and NIHSS score of edaravone combined with clopidogrel in patients with acute cerebral infarction

Objective To explore the efficacy of the observation of the the edaravone united clopidogrel therapy in patients with acute cerebral infarction and NIHSS score. Methods All cases were from 64 patients with acute cerebral infarction patients admitted in our hospital in March 2010-March 2011 in according to the different treatment methods into treatment group （edaravone combined with clopidogrel therapy） and control group （ edaravone treatment） of the 32 cases, efficacy and treatment were compared between the two groups after treatment 14 d after 7 days of treatment, the treatment of the the 14 d after two groups of the NIHSS changes. Results The efficacy of the treatment group and the control group after treatment 14 d comparison, 93.8% ＆ 75.0%, a significant difference （P 〈 0.05）. After 7 days of treatment, NIHSS score compared with the two groups before treatment was significantly decreased in the treatment group than in the control group decreased more significantly（P 〈 0.05）; Treatment after 14 days, 7 days, NIHSS score of the two groups were compared with pre-treatment and post-treatment significantly reduced, and the treatment group compared with the control group decreased more significantly （P 〈 0.05）. Conclusion Edaravone and clopidogrel associated with the treatment of acute cerebral infarction have a synergistic effect, can effectively improve neurological deficit, improve clinical outcomes, worthy of promotion and application.